The European Medicines Agency EMA is examining the approval of another corona drug. The Swiss pharmaceutical company Roche has submitted an application for approval of its antibody therapy Ronapreve, the EMA announced on Monday in Amsterdam. The drug, which consists of two active ingredients (casirivimab and imdevimab) and was co-produced by the US manufacturer Regeneron Pharmaceuticals, is intended to treat people from the age of twelve who are infected with the coronavirus and have a high risk of a severe course.
In addition, according to the manufacturer, the agent can also be used in people who have an acute risk of infection, for example because they live in a household with an infected person.
Recommended by the WHO
Only recently, the World Health Organization (WHO) recommended the cocktail of casirivimab and imdevimab for the prevention of severe Covid 19 disease in infected risk patients.
So far, only the drug Remdesivir has been approved as a special corona drug in the EU. A total of five preparations are currently being approved.